In 2011, Stason Animal Health (SAH) was formed and currently offers a vertically integrated, value-added platform for drug development, manufacturing, distribution, marketing, and sales of pet health products into veterinary hospitals and retail drug stores.

(more information on SAH)

US companies team up to offer US Biologics and Biosimilar expertise to Asian manufacturers and drug developers

(open full press release .pdf)

Stason and Lonza Sign Agreement to License the GS Gene Expression System™ to Develop and Manufacture TNT Antibodies

(open full press release .pdf)

Unilife and Stason Pharmaceuticals Sign Asian Distribution Agreement for the Unitract™ 1mL Safety Syringe

(open full press release .pdf)

Peregrine Pharmaceuticals and Stason Pharmaceuticals to Pursue Tumor Necrosis Therapy Development Pact in Asia

(open full press release .pdf)